Searched for
PAR PHARMACEUTICALS INC
India’s cheap birth control pills in US could vanish under Trump’s 250% tariff threatDonald Trump's tariff threat jeopardizes affordable Indian medicines in the US. Birth control pills, hypertension, and depression treatment...- Pharma industry to outdo India Inc in 2025 pay hike: StudyPharma companies in India are projected to offer an average salary increment of 9.6% in 2025, slightly lower than the previous year but sti...
- Asian stocks drop after AI jitters hit US equitiesA selloff was triggered after a cheap AI model from Chinese startup DeepSeek climbed to the top of Apple’s appstore, sparking concerns that...
- French drugmaker Sanofi looks to spin off its consumer business in IndiaThe leading vaccine maker is working with Bank of America on the demerger process, said the people cited above. About 60% of Sanofi India i...
- Glenmark launches generic version of Zetia in US market"We have launched ezetimibe, the first and only generic version of Zetia (Merck) in the United States for the treatment of high cholesterol...
- GAVIS Pharma LLC looking to exit Bengaluru-based Wintac LtdGavis Pharma LLC is now exploring options to exit its listed Indian arm. Wintac Ltd was not part of the 2015 deal struck between Lupin & Ga...
- Settlement of Somaxon Pharmaceuticals patent suit in US soon: ZydusAhmedabad-based Zydus Cadila says, it agreed to settle a patent litigation suit with US-based Somaxon Pharmaceuticals for insomnia drug – S...
- Pfizer to sell animal health biz to subsidiary for Rs 440 crPharmaceuticals firm Pfizer today said it will hive off its animal health division to a wholly-owned subsidiary for a consideration of Rs 4...
- Money inflow intact, 4 pharma FDI plans okayedThe Foreign Investment Promotion Board (FIPB) examines FDI proposals that are on the approval route, but in the case of pharmaceutical sect...
- US Food and Drug Administration approves generic versions of schizophrenia drugUS Food and Drug Administration (FDA) has approved the first generic versions of Zyprexa and Zyprexa Zydus, used for treating schizophrenia...
- Home-grown jugaad set for patent coverThe idea was to give intellectual property rights to the small scale industry's innovations that lead to inventions which do not strictly c...
- Deloitte sees lots of money pouring into IndiaThe global M&A scene is bustling with multi-billion dollar transactions as many companies are flush with funds, after lying dormant during ...
- Pfizer’s growth outlook seen strongThe Pfizer stock has offered better returns to investors than the Bombay Stock Exchange’s (BSE) benchmark index, the Sensex, over the past ...
- Merck, Glenmark end cholesterol drug rowCos opt for out-of-court settlement; Merck to refund $20-mn litigation costs.
- Glenmark inks licence, supply pact with TaroGlenmark Pharmaceuticals on Thursday said it has signed a licence and supply agreement with Israeli firm Taro Pharmaceuticals to sell a bra...
- Sanofi to expand in emerging markets to bolster growthSanofi-Aventis will continue “shopping” for acquisitions to build its vaccine, biotechnology and non-prescription medicine businesses, as w...
- GSK enters into agreement with Japan-based Astellas PharmaDrug firm GlaxoSmithkline Pharmaceuticals on Monday said it has enter into a collaboration with the Japan-based Astellas Pharma Inc for sel...
- Indian drug makers eye US firm Par PharmaIndia's top drug makers are in the race to acquire US-based generic drug maker, Par Pharmaceutical Co Inc, two Indian newspapers reported o...
- Salary medians north bound, cash in!Average salary increases in many sectors here have leapt from about 15% in yesteryear to 20% levels.
- Orchid to acquire European firmThe Chennai-based drug maker Orchid Chemicals & Laboratories has set its eyes on the high-value global injectibles market with plans to acq...
Load More
